Glossary
therapeutic duplication
Therapeutic duplication is two drugs from the same therapeutic class — or the same drug under two names — on one patient profile at the same time. It is a routine DUR screening category.
Therapeutic duplication is the presence of two or more medications of the same therapeutic class — or the same drug under two names — on one patient's profile at the same time. It is one of the screening categories a drug utilization review runs at the point of adjudication, which is why a technician sees it as a claim alert rather than as a theory.
The obvious cases are two drugs from one class: two NSAIDs, two benzodiazepines, two SSRIs, two opioids, two anticoagulants. The less obvious ones hide in combination products and in the over-the-counter aisle: an opioid/acetaminophen tablet plus a separate acetaminophen bottle, a prescription antihistamine plus an OTC sleep aid with the same ingredient, pseudoephedrine in two different cold products, or the same drug dispensed once as a brand and once as a generic. The active ingredient, not the brand name, is the test.
What the category asks of a technician is a decision about who acts. A duplication alert is a pharmacist intervention: the technician's job is to recognize the pattern, hold the fill and route it — not to refuse the prescription or to tell the patient which drug to stop. Duplication is also one of the reasons the profile has to be complete, because a duplicate can only be seen against the medication history the pharmacy already holds.
Taught in
Related terms
- high-alert medication — A high-alert medication is one that bears a heightened risk of significant harm when it is used in error — insulin, heparin, opioids, concentrated electrolytes. The risk is the harm, not a higher error rate.
- days supply — Days supply is how long a dispensed quantity is meant to last: the quantity divided by the amount taken per day. It comes from the sig, not from the size of the package.
Source: PTCB — PTCE Content Outline, effective January 6, 2026 (the KA 1.2 statement "Therapeutic duplications", the KA 2.2 and 2.3 statements on controlled substances and prescription requirements, the KA 4.3 and 4.4 statements on NDC, lot, expiration and returns, and the KA 3.1/3.2 error-prevention statements, quoted verbatim); FDA label and NDC data read through openFDA and DailyMed; ISMP (the high-alert medication definition and the error-prone abbreviation list); USP <795> and <797>; the DEA Pharmacist's Manual (outline accessed 2026-10-03, verbatim; every fact below restates this course's own guides, which carry the per-source citations on their own pages (FDA, ISMP, USP and DEA each publish on its own schedule))